B+
Bull case
30%
Probability
Target price
$88.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
LIVN
LivaNovaCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The strongest post-print read is straightforward: core franchises accelerated, guidance moved higher, and the company now has both a fresh FDA approval and a visible OSA launch roadmap. Secondary market-data sources indicated Q1 results were above pre-report consensus on both revenue and adjusted EPS, which supports a higher forward setup if estimate revisions follow.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.0.
What can break
Neuromodulation growth remained solid, but adjusted segment margin in that segment eased year over year, showing that not all operating leverage is flowing through cleanly [#8-K-2026-05-06].
Momentum
45
Value
56
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $81.20 · Bull $88.00 · Bear $60.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $90.67
Why
Momentum45 · Δ7d +10.9
Value56 · Δ7d -0.0
Sentiment62 · Δ7d +5.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.0.
Contradictions & invalidation
- • Neuromodulation growth remained solid, but adjusted segment margin in that segment eased year over year, showing that not all operating leverage is flowing through cleanly [#8-K-2026-05-06].
- • OSA is still in an early launch phase; the earnings slides show a limited market release in H2 2026 and full market release in H1 2027, so commercialization and reimbursement execution remain open risks [#8-K-2026-05-06].
- • This is still a monitoring-style medtech thesis rather than a clean breakout.
Catalyst clock
2026-05-06
Q1 beat-and-raise resets near-term expectations
Lead driver: Sentiment · See AI snapshot
Momentum
45
9% active weight
Current posture
7d trendImproving
Δ7d
+10.9
Δ21d
-26.0
Value
56
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
62
62% active weight
Current posture
7d trendImproving
Δ7d
+5.0
Δ21d
+0.8
Why this grade
Composite grade C. Momentum 45.2 / Value 56.1 / Sentiment 62.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$81.20
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4.49B
Beta
0.97
Shares Out
55.09M
P/E (TTM) · Derived
-18.3
P/S (TTM)
2.56
P/FCF (TTM)
18.04
Rev YoY
+10.8%
EPS YoY
+288.6%
Gross Margin
+68.2%
Op Margin
+15.0%
Net Debt
-$201.78M
Current Ratio
1.45
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data